Biomarkers, interventions and healthy ageing

Almas Kenessary, Zhaxybay Zhumadilov, Talgat Nurgozhin, David Kipling, Mark Yeoman, Lynne Cox, Elizabeth Ostler, Richard Faragher

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Population ageing is probably the single most important healthcare challenge the developed and developing world will face in the 21st century. This is because the later part of the human life course is marked by the emergence of a wide spectrum of pathological impairments which increase morbidity and reduce quality of life. The processes driving these increases in mortality and morbidity are often conceptualised as highly complex and multi-causal. Indeed, it has been suggested that there is no human 'ageing process', only distinct, disease-specific mechanisms of pathology. However, humans are not the only organisms within the biosphere to show ageing and the use of cross-species approaches has demonstrated that common ageing processes exist and allowed some of the common genetic pathways controlling them to be identified. Mutants in these pathways either delay or accelerate the development of late life diseases giving rise to extended healthy lives or progerias, respectively. These advances in fundamental understanding open opportunities for a more detailed investigation of the key causal mechanisms underlying ageing and the exploitation of that knowledge for improved interventions in later life.

Original languageEnglish
Pages (from-to)373-377
Number of pages5
JournalNew Biotechnology
Volume30
Issue number4
DOIs
Publication statusPublished - May 25 2013

Fingerprint

Biomarkers
Aging of materials
Morbidity
Quality of Life
Pathology
Delivery of Health Care
Mortality
Population

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Biology
  • Bioengineering
  • Medicine(all)

Cite this

Kenessary, A., Zhumadilov, Z., Nurgozhin, T., Kipling, D., Yeoman, M., Cox, L., ... Faragher, R. (2013). Biomarkers, interventions and healthy ageing. New Biotechnology, 30(4), 373-377. https://doi.org/10.1016/j.nbt.2012.11.018

Biomarkers, interventions and healthy ageing. / Kenessary, Almas; Zhumadilov, Zhaxybay; Nurgozhin, Talgat; Kipling, David; Yeoman, Mark; Cox, Lynne; Ostler, Elizabeth; Faragher, Richard.

In: New Biotechnology, Vol. 30, No. 4, 25.05.2013, p. 373-377.

Research output: Contribution to journalArticle

Kenessary, A, Zhumadilov, Z, Nurgozhin, T, Kipling, D, Yeoman, M, Cox, L, Ostler, E & Faragher, R 2013, 'Biomarkers, interventions and healthy ageing', New Biotechnology, vol. 30, no. 4, pp. 373-377. https://doi.org/10.1016/j.nbt.2012.11.018
Kenessary A, Zhumadilov Z, Nurgozhin T, Kipling D, Yeoman M, Cox L et al. Biomarkers, interventions and healthy ageing. New Biotechnology. 2013 May 25;30(4):373-377. https://doi.org/10.1016/j.nbt.2012.11.018
Kenessary, Almas ; Zhumadilov, Zhaxybay ; Nurgozhin, Talgat ; Kipling, David ; Yeoman, Mark ; Cox, Lynne ; Ostler, Elizabeth ; Faragher, Richard. / Biomarkers, interventions and healthy ageing. In: New Biotechnology. 2013 ; Vol. 30, No. 4. pp. 373-377.
@article{94d87cfd159c4886adb0ffc91acda033,
title = "Biomarkers, interventions and healthy ageing",
abstract = "Population ageing is probably the single most important healthcare challenge the developed and developing world will face in the 21st century. This is because the later part of the human life course is marked by the emergence of a wide spectrum of pathological impairments which increase morbidity and reduce quality of life. The processes driving these increases in mortality and morbidity are often conceptualised as highly complex and multi-causal. Indeed, it has been suggested that there is no human 'ageing process', only distinct, disease-specific mechanisms of pathology. However, humans are not the only organisms within the biosphere to show ageing and the use of cross-species approaches has demonstrated that common ageing processes exist and allowed some of the common genetic pathways controlling them to be identified. Mutants in these pathways either delay or accelerate the development of late life diseases giving rise to extended healthy lives or progerias, respectively. These advances in fundamental understanding open opportunities for a more detailed investigation of the key causal mechanisms underlying ageing and the exploitation of that knowledge for improved interventions in later life.",
author = "Almas Kenessary and Zhaxybay Zhumadilov and Talgat Nurgozhin and David Kipling and Mark Yeoman and Lynne Cox and Elizabeth Ostler and Richard Faragher",
year = "2013",
month = "5",
day = "25",
doi = "10.1016/j.nbt.2012.11.018",
language = "English",
volume = "30",
pages = "373--377",
journal = "New Biotechnology",
issn = "1871-6784",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Biomarkers, interventions and healthy ageing

AU - Kenessary, Almas

AU - Zhumadilov, Zhaxybay

AU - Nurgozhin, Talgat

AU - Kipling, David

AU - Yeoman, Mark

AU - Cox, Lynne

AU - Ostler, Elizabeth

AU - Faragher, Richard

PY - 2013/5/25

Y1 - 2013/5/25

N2 - Population ageing is probably the single most important healthcare challenge the developed and developing world will face in the 21st century. This is because the later part of the human life course is marked by the emergence of a wide spectrum of pathological impairments which increase morbidity and reduce quality of life. The processes driving these increases in mortality and morbidity are often conceptualised as highly complex and multi-causal. Indeed, it has been suggested that there is no human 'ageing process', only distinct, disease-specific mechanisms of pathology. However, humans are not the only organisms within the biosphere to show ageing and the use of cross-species approaches has demonstrated that common ageing processes exist and allowed some of the common genetic pathways controlling them to be identified. Mutants in these pathways either delay or accelerate the development of late life diseases giving rise to extended healthy lives or progerias, respectively. These advances in fundamental understanding open opportunities for a more detailed investigation of the key causal mechanisms underlying ageing and the exploitation of that knowledge for improved interventions in later life.

AB - Population ageing is probably the single most important healthcare challenge the developed and developing world will face in the 21st century. This is because the later part of the human life course is marked by the emergence of a wide spectrum of pathological impairments which increase morbidity and reduce quality of life. The processes driving these increases in mortality and morbidity are often conceptualised as highly complex and multi-causal. Indeed, it has been suggested that there is no human 'ageing process', only distinct, disease-specific mechanisms of pathology. However, humans are not the only organisms within the biosphere to show ageing and the use of cross-species approaches has demonstrated that common ageing processes exist and allowed some of the common genetic pathways controlling them to be identified. Mutants in these pathways either delay or accelerate the development of late life diseases giving rise to extended healthy lives or progerias, respectively. These advances in fundamental understanding open opportunities for a more detailed investigation of the key causal mechanisms underlying ageing and the exploitation of that knowledge for improved interventions in later life.

UR - http://www.scopus.com/inward/record.url?scp=84877832564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877832564&partnerID=8YFLogxK

U2 - 10.1016/j.nbt.2012.11.018

DO - 10.1016/j.nbt.2012.11.018

M3 - Article

VL - 30

SP - 373

EP - 377

JO - New Biotechnology

JF - New Biotechnology

SN - 1871-6784

IS - 4

ER -